Clinical trials: Adults With Overweight and Obesity
Obesity, Overweight
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05669599
- Testing
- Maridebart Cafraglutide
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 592 people
- Sponsor
- Amgen
Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver…
- Trial name
- NCT07441252
- Testing
- Maridebart cafraglutide
- Where
- 23 sites in United States
- Volunteers
- 180 people
- Sponsor
- Amgen
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Overweight, Obese
A Study of CT-868 in Type 1 Diabetes Mellitus
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo.
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Trial name
- NCT06062069
- Testing
- CT-868, CT-868 Pen Injector
- Where
- 22 sites in United States
- Volunteers
- 111 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity and Overweight, Dysbiosis
Effect of Watermelon on Gut and Cardiometabolic Health
The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and…
- Trial name
- NCT06588218
- Testing
- Watermelon, Belvita Breakfast Sandwich + 12 oz Water
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Florida State University
Obesity Associated Disorder
Changes in Muscle Strength, Inflammatory Markers, and Body Composition in Response to Alternate Day Fasting Combined With Krill Oil Supplementation in Adults With Overweight and Obesity
The goal of this double-blind, randomised, controlled trial is to determine the effects of LC n-3 PUFAs supplementation on changes in body composition and muscle strength during body weight loss and body weight maintenance among…
- Trial name
- NCT06001632
- Testing
- krill oil (SuperbaBoostTM), 4g/day of mixed vegetable oil
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Obesity, Overweight
Reset: Enhancing Weight Loss in a Digital Intervention
The goal of the Reset trial is to learn about the optimal combination of dietary behavior strategies in a fully digital weight loss intervention. The intervention is designed for adults with overweight or obesity.
- Conditions
- Obesity, Overweight, Weight Loss, Health Behavior
- Trial name
- NCT07032571
- Testing
- Core Behavioral Weight Loss Intervention, Limit Red Zone Foods, Limit Eating Window
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Stanford University
Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a common and serious complication of obesity and type 2 diabetes (T2D). HFpEF occurs when the heart muscle unable to relax efficiently to pump the blood around the body.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
- Trial name
- AMEND (NCT05887271)
- Testing
- Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography
- Where
- 3 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- University of Leicester
Overweight and Obesity
High Vitamin K Intake Diet Intervention Effect on Cardiovascular Risk Percentage in Young Adults
The goal of this clinical trial is to compare the effect of a high vitamin K diet intervention on vitamin K, insulin, osteocalcin serum levels and the cardiovascular risk percentage in normal weight and overweight or obese young…
- Trial name
- VKDI (NCT06250647)
- Testing
- vitamin K diet
- Where
- Mexico
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Obesity & Overweight
Effect of High-intensity Interval Training on Cardiometabolic Health and Physical Fitness in Young Adults With Obesity
The objective of the present project is to compare the effects of two types of training on cardiovascular health components and physical fitness in young adults with obesity.
- Trial name
- NCT07283406
- Testing
- High-intensity interval training intervention, Moderate-intensity continuous training intervention, Educational sessions
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Centro Universitario de Tlajomulco, Universidad de Guadalajara
Mobility Limitation, Overweight or Obesity
Functional Fitness for Overweight or Obese Adults With Mobility Disabilities
Over 64 million people in the U.S. have a permanent disability, with mobility-related disability (MRD) representing the most prevalent disability type (13.7%).
- Conditions
- Mobility Limitation, Overweight or Obesity, Physical Disability
- Trial name
- COBRE Pilot (NCT05880966)
- Testing
- Functional Fitness
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Pre-diabetes
A Smartphone-based Intervention for Diabetes Prevention in Overweight Chinese Adults With Pre-diabetes
Type 2 diabetes (T2DM) is a serious chronic condition and one of the world's fastest growing health problems. The onset of T2DM is gradual, with most individuals progressing through a state of pre-diabetes, which provides an…
- Trial name
- NCT04875780
- Testing
- Digital diabetes prevention app intervention, Digital weight loss tracking app intervention, Wait-list control (usual care)
- Where
- Hong Kong
- Volunteers
- 282 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes Mellitus
A Trial Evaluating the Effects of a One-year Lifestyle Intervention in Obese Patients With Type 2 Diabetes
Diabetic patients with uncontrolled disease are often characterized by increased energy expenditure and could thus present a high resting metabolic rate (RMR).
- Trial name
- NCT03785379
- Testing
- Caloric restriction, Exercise training
- Volunteers
- 23 people
- Sponsor
- University of Padova
Obesity, Overweight
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2…
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- AMPLIFY-2 (NCT07881458)
- Testing
- eloralintide and tirzepatide, Tirzepatide
- Where
- 75 sites in United States, Brazil and 8 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
It is estimated that by 2030 one in five women and one in seven men will be obese, equivalent to more than 1 billion people around the world.
- Trial name
- HIFCT-V (NCT05619874)
- Testing
- HIFCT-S, HIFCT-P
- Where
- Colombia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Universidad de Antioquia
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Obesity, Overweight
Semaglutide for Post-Smoking Cessation Weight Management
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
- Conditions
- Obesity, Overweight, Cigarette Smoking
- Trial name
- NCT06173778
- Testing
- semaglutide 2.4mg, Nicotine Replacement Therapy (NRT, nicotine patch), Brief Smoking Cessation Counseling
- Where
- 2 sites in United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Obesity, Metabolic Syndrome
Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat.
- Conditions
- Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT00352287
- Testing
- Recombinant human growth hormone; pioglitazone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Stanford University